Isotechnika Pharma has signed a global development and commercialization license agreement with Vifor Pharma Ltd., granting Vifor an exclusive license for its lead drug, voclosporin, for the treatment of lupus and all proteinuric nephrology indications. The license is for the U.S. and other regions outside of Canada, South Africa, Israel, China, Taiwan and Hong Kong. Isotechnika is eligible to receive upfront and milestone payments, as well as royalties on commercial sales. Vifor will also purch...